Olema Pharmaceuticals (OLMA) to Release Earnings on Tuesday

Olema Pharmaceuticals (NASDAQ:OLMA) is expected to release its Q1 2026 results before the market opens on Tuesday, May 12th. Analysts expect Olema Pharmaceuticals to post earnings of ($0.52) per share for the quarter. Individuals may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Friday, May 22, 2026 at 9:30 AM ET.

Olema Pharmaceuticals (NASDAQ:OLMA) last released its quarterly earnings results on Monday, March 16th. The company reported ($0.50) EPS for the quarter, topping the consensus estimate of ($0.51) by $0.01. On average, analysts expect Olema Pharmaceuticals to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Olema Pharmaceuticals Price Performance

OLMA stock opened at $14.90 on Monday. The stock’s 50 day moving average is $16.58 and its two-hundred day moving average is $20.27. Olema Pharmaceuticals has a 52-week low of $3.89 and a 52-week high of $36.26. The company has a market capitalization of $1.30 billion, a PE ratio of -8.01 and a beta of 2.05. The company has a quick ratio of 9.95, a current ratio of 9.95 and a debt-to-equity ratio of 0.01.

Insider Activity

In related news, insider Shawnte Mitchell sold 25,000 shares of the firm’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $24.25, for a total transaction of $606,250.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 12.56% of the company’s stock.

Institutional Trading of Olema Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the business. Russell Investments Group Ltd. bought a new position in shares of Olema Pharmaceuticals in the 3rd quarter worth about $53,000. American Century Companies Inc. bought a new stake in shares of Olema Pharmaceuticals during the 2nd quarter valued at about $54,000. Creative Planning bought a new stake in shares of Olema Pharmaceuticals during the 2nd quarter valued at about $83,000. The Manufacturers Life Insurance Company raised its stake in Olema Pharmaceuticals by 46.7% during the second quarter. The Manufacturers Life Insurance Company now owns 22,442 shares of the company’s stock worth $96,000 after acquiring an additional 7,146 shares during the period. Finally, AQR Capital Management LLC acquired a new stake in Olema Pharmaceuticals during the first quarter worth about $172,000. Institutional investors own 91.78% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently issued reports on OLMA shares. Oppenheimer restated an “outperform” rating on shares of Olema Pharmaceuticals in a research note on Monday, March 9th. JPMorgan Chase & Co. increased their price objective on shares of Olema Pharmaceuticals from $55.00 to $58.00 and gave the company an “overweight” rating in a research note on Wednesday, March 18th. Stifel Nicolaus began coverage on shares of Olema Pharmaceuticals in a report on Wednesday, February 11th. They set a “buy” rating and a $48.00 price objective for the company. TD Cowen reissued a “buy” rating on shares of Olema Pharmaceuticals in a research report on Monday, March 9th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Olema Pharmaceuticals in a research note on Tuesday, April 21st. Eleven investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Olema Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $44.40.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.